A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

NCT02223247 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Malignant Tumor

Interventions

DRUG: TVB-2640

Sponsor

Sagimet Biosciences Inc.